India's central procurement agency for medicines and other medical products reportedly has lowered some of its standards to allow smaller companies to bid on large contracts for malaria drugs, condoms and other items.
Generic drug companies Dr Reddy's Laboratories and Natco Pharma gained more than 2% on Monday as Mylan said its Indian unit will start sales of Gilead Sciences' Sovaldi (sofosbuvir 400) in India, a move that diminishes the likelihood of compulsory licensing of the drug as generic copies have already been licensed to local companies.
India and a group of four European nations, including Switzerland, have broken off trade talks over a failure to resolve differences involving India's protections for intellectual property rights, particularly pharmaceuticals.
Once again, more than half of the countries on the U.S. Trade Representative's Priority Watch List for insufficient intellectual-property protection are in Asia. Four other Asia countries also were named to the Watch List as being of lesser concern.
The Drug Controller General of India, G.N. Singh, told India Today the government has been working with Hilleman on a proposal to research and develop formulations of oral rotavirus vaccines that are thermostable across a variety of temperatures and environmental conditions.
If you thought Sun Pharmaceutical Industries would rest on its laurels after buying Ranbaxy Laboratories in India's largest pharma deal, think again. Sun apparently has another $7 billion burning a proverbial hole in its pocket and is looking for more, more, more.
Is the law of unintended consequences about to be visited on the drug industry in India, much as it already has in neighbor China? There is evidence a middle-class is rising in India, threatening its attraction as a low-priced place for outsourced drug production.
Cipla offered a compromise of sorts to Novartis through the Delhi High Court, where it is appealing a stay order on producing a generic of the Swiss drugmaker's Onbrez (indacaterol) for respiratory diseases. Novartis rejected the offer outright.
India's pharmaceutical regulators are considering whether to take the rigid steps necessary to join international drug inspection systems. The actions are considered necessary if India is to become more of an exporting nation, but some pharmas are cautious.
India's drug minister said there was a misconception in the nation--including in its media--that prices of pharmaceuticals had skyrocketed recently. Ananth Kumar noted that 350 additional drugs had been brought under price controls in the past 10 months and other plans are already driving down costs.